Everest and Providence report positive Phase II data for Covid-19 vaccine

Everest Medicines and its partner Providence Therapeutics have reported positive findings from the Phase II PRO-CL-002 clinical trial of a messenger ribonucleic acid (mRNA) Covid-19 vaccine candidate, PTX-COVID19-B.